Business Description

Astellas Pharma, Inc. is involved in the manufacturing, import, development, and exportation of pharmaceutical products. Kenji Yamanouchi founded the company in April 1923. It is headquartered in Tokyo. Its products focus on therapeutic areas such as transplantation, immunology and neurology, diabetes complications, infectious diseases, and metabolic diseases. Prograf, Vesicare, and Protopic are the global brands of the firm. Harnal and Funguard are also among them.

Key Financials

Revenue (US$ Mn):

• US$ 11,257 Mn was the annual revenue generated by Astellas Pharma, Inc. in 2021
• Astellas Pharma, Inc.’s annual revenue for 2020 was US$ 11,583 Mn, a -1.28% decrease from 2019
• From 2018’s annual revenues, Astellas Pharma, Inc. registered a -4.55% decrease in 2019, amounting to US$ 11,734 Mn
• Total revenue of US$ 12,293 Mn was generated in 2018 by Astellas Pharma, Inc.

Operating Income (US$ Mn):

• Astellas Pharma, Inc.’s operating income for 2021 was US$ 1,226 Mn, a -2.45% decrease from 2020
• The operating income generated by Astellas Pharma, Inc. in 2020 was US$ 1,257 Mn
• At a -4.1% decrease from , Astellas Pharma, Inc.’s operating income of US$ 2,216 Mn was indexed in 2019
• Astellas Pharma, Inc. generated an operating income of US$ 2,311 Mn in 2018

Net Income (US$ Mn):

• Astellas Pharma, Inc.’s net income for 2021 was US$ 1,086 Mn, a -2.85% decrease from 2020
• The net income generated by Astellas Pharma, Inc. in 2020 was US$ 1,118 Mn
• At a -15.73% decrease from , Astellas Pharma, Inc.’s net income of US$ 1,763 Mn was indexed in 2019
• Astellas Pharma, Inc. generated a net income of US$ 2,092 Mn in 2018

Operating Margin %:

• 18% was the operating margin generated by Astellas Pharma, Inc. in 2021
• Astellas Pharma, Inc.’s operating margin for 2020 was 80%, a 2.03% increase from 2019
• From 2018’s operating margins, Astellas Pharma, Inc. registered a 1.42% increase in 2019, amounting to 79%
• An operating margin of 78% was generated in 2018 by Astellas Pharma, Inc.

Gross Margin %:

• Astellas Pharma, Inc.’s gross margin for 2021 was 80%, a 637.96% increase from 2020
• The gross margin generated by Astellas Pharma, Inc. in 2020 was 11%
• At a 0.53% increase from , Astellas Pharma, Inc.’s gross margin of 19% was indexed in 2019
• Astellas Pharma, Inc. generated a gross margin of 19% in 2018

SWOT Analysis

Strengths

Acquisition of iota Biosciences Inc

The acquisition is a key part of the company’s growth strategy. Astellas Pharma signed an agreement in October 2020 to acquire iota Biosciences, Inc. The acquisition will allow the company to increase its Rx+ business. It will also expedite the Rx+ projects that were previously covered by the R&D agreement between the parties signed in August 2019. This acquisition allows for the exploration of new applications of iota’s bioelectronics tech for target diseases and the development of new technologies.

Get this premium content

The Premium data is Locked

Buy Now to Unlock Premium Data

Request Sample Data